SynAct Pharma AB financials
SynAct Pharma AB
549300RRYIEFEQ72N546 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 0 | SEK 0 |
| Gross profit | SEK 0 | SEK 0 |
| Other income | SEK 136.0K | SEK 41.0K |
| Operating profit (EBIT) | -SEK 90.0M | -SEK 224.5M |
| Finance costs | SEK 3.0M | SEK 830.0K |
| Profit before tax | -SEK 90.8M | -SEK 224.3M |
| Income tax expense | -SEK 8.4M | -SEK 8.5M |
| Profit for the year | -SEK 82.4M | -SEK 215.8M |
| — attributable to owners | -SEK 82.4M | -SEK 215.8M |
| Total comprehensive income | -SEK 79.9M | -SEK 202.8M |
| Per share | ||
| Basic EPS | SEK -2.08 | SEK -6.64 |
| Diluted EPS | SEK -2.08 | SEK -6.64 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 89.2M | -SEK 100.2M |
| Net cash from investing activities | SEK 0 | SEK 370.0K |
| Net cash from financing activities | SEK 87.4M | SEK 54.0M |
| Lease liability payments | SEK 596.0K | SEK 729.0K |
| Net change in cash | -SEK 1.8M | -SEK 45.8M |
| Balance sheet | ||
| Total assets | SEK 270.5M | SEK 228.0M |
| Non-current assets | SEK 156.7M | SEK 153.0M |
| Right-of-use assets | SEK 1.9M | SEK 660.0K |
| Current assets | SEK 94.0M | SEK 75.1M |
| Cash & equivalents | SEK 61.2M | SEK 62.4M |
| Total equity | SEK 214.2M | SEK 176.2M |
| — attributable to owners | SEK 214.2M | SEK 176.2M |
| Non-current liabilities | SEK 27.9M | SEK 26.9M |
| Lease liabilities (non-current) | SEK 1.3M | SEK 58.0K |
| Current liabilities | SEK 28.5M | SEK 24.9M |
| Lease liabilities (current) | SEK 595.0K | SEK 579.0K |
| Trade & other payables | SEK 17.3M | SEK 9.7M |
| Deferred tax liabilities | SEK 18.3M | SEK 18.0M |
| Derived metrics | ||
| Return on equity | -38.5% | -122.5% |
| Cash conversion ratio | 1.08× | 0.46× |
| Other reported items | ||
| Accruals Classified As Current | SEK 10.1M | SEK 9.8M |
| Additional Paidin Capital | SEK 762.8M | SEK 646.6M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -SEK 19.6M | SEK 19.9M |
| Adjustments For Increase Decrease In Other Current Liabilities | -SEK 6.0M | SEK 5.4M |
| Adjustments For Increase Decrease In Trade Account Payable | SEK 7.3M | SEK 5.1M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 70.9M | -SEK 130.5M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 79.9M | -SEK 202.8M |
| Current Prepaid Expenses | SEK 18.4M | SEK 258.0K |
| Current Tax Assets Current | SEK 8.5M | SEK 8.2M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 607.0K | -SEK 27.0K |
| Equity and Liabilities | SEK 270.5M | SEK 228.0M |
| Finance Income | SEK 2.1M | SEK 1.1M |
| General and Administrative Expense | SEK 40.5M | SEK 44.8M |
| Income Taxes Paid Refund Classified As Operating Activities | -SEK 8.4M | -SEK 8.5M |
| Increase Decrease Through Acquisition of Subsidiary | — | SEK 189.9M |
| Increase Decrease Through Sharebased Payment Transactions | SEK 10.1M | SEK 7.9M |
| Increase Decrease Through Transactions With Owners | SEK 117.9M | SEK 252.5M |
| Interest Paid Classified As Operating Activities | SEK 978.0K | SEK 123.0K |
| Interest Received Classified As Operating Activities | SEK 778.0K | SEK 34.0K |
| Issue of Equity | — | SEK 59.5M |
| Issued Capital | SEK 5.8M | SEK 4.4M |
| Noncurrent Financial Assets | SEK 144.0K | SEK 139.0K |
| Noncurrent Financial Liabilities At Fair Value Through Profit Or Loss | SEK 8.0M | SEK 7.2M |
| Other Adjustments For Noncash Items | SEK 10.8M | SEK 85.6M |
| Other Comprehensive Income | SEK 2.5M | SEK 13.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | SEK 2.5M | SEK 13.0M |
| Other Current Liabilities | SEK 424.0K | SEK 4.9M |
| Other Current Receivables | SEK 6.0M | SEK 4.2M |
| Other Expense By Function | SEK 311.0K | SEK 74.7M |
| Other Inflows Outflows of Cash Classified As Investing Activities | SEK 0 | SEK 370.0K |
| Other Intangible Assets | SEK 154.6M | SEK 152.2M |
| Other Longterm Provisions | SEK 331.0K | SEK 1.6M |
| Payments For Share Issue Costs | SEK 6.1M | SEK 4.7M |
| Proceeds From Issuing Shares | SEK 94.1M | SEK 59.5M |
| Research and Development Expense | SEK 49.3M | SEK 105.1M |
| Reserve of Exchange Differences On Translation | SEK 18.2M | SEK 15.8M |
| Retained Earnings | -SEK 573.0M | -SEK 490.6M |
| Share Issue Related Cost | SEK 6.1M | SEK 4.7M |
Every line item above is a fact tagged in SynAct Pharma AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.